

Supplemental Table S1. Preprocedural evaluation of treated patients, grouped by indication for LAAC.

Parameter	Indication for LAAC			P value	
	Bleeding	Thromboembolism	Other	Overall	Post-hoc
Laboratory					
Haemoglobin, g/dL	12.9±2.0	14.6±1.3	12.6±1.9	0.002	**,††
ntProBNP, mg/dL	979 (433-1913)	618 (486-1464)	755 (275-1528)	0.534	
Creatinine, mg/dL	1.1 (1.0-1.4)	1.1 (1.0-1.2)	1.1 (1.0-2.3)	0.339	
Echocardiography					
Left-ventricular function				0.659	
35-50%	16.2%	6.7%	13.3%		
<35%	13.5%	12.7%	6.7%		
Patent foramen ovale	9.9%	20.0%	11.7%	0.510	
LAA minimum orifice diameter, mm (n=58)	17.0±4.3	19.5±2.7	16.1±3.7	0.277	
LAA maximum orifice diameter, mm (n=58)	20.8±4.6	23.0±3.2	19.3±4.1	0.222	
Baseline medication					
VKA	9.0%	6.7%	20.0%	0.104	
DOAC	23.4%	80.0%	28.3%	<0.001	**,††
Aspirin	19.8%	13.3%	31.7%	0.155	
Adenosine diphosphate receptor inhibitor	13.5%	0%	14.0%	0.190	
Low molecular weight heparin	25.2%	6.7%	25.0%	0.303	
Dual antiplatelet therapy	6.3%	0%	13.3%	0.177	

DOAC: direct oral anticoagulant; LAA: left atrial appendage; LAAC: left atrial appendage closure; VKA: vitamin K antagonist. The following symbols represent significant differences in post-hoc testing (after Bonferroni adjustment): bleeding vs embolism: ** p<0.01; bleeding vs other: †† p<0.01; embolism vs other: †† p<0.01.

Supplemental Table S2. Procedural outcome and follow-up echocardiography.

Parameter	Indication for LAAC			P value	
	Bleeding	Thromboembolism	Other	Overall	Post-hoc
Technical details					
LAAC only	89.8%	73.3%	81.8%	0.113	
Concomitant PFO closure	7.1%	26.7%	12.7%	0.055	
Concomitant transcatheter mitral-valve repair	1.0%	0.0%	3.6%	0.467	
Concomitant coronary angiography +/- percutaneous intervention	3.1%	0.0%	0.0%	0.663	
Implanted device				0.038	§
Amplatzer™	47.7%	86.7%	51.7%		
Watchman™	50.5%	13.3%	48.3%		
other/none implanted	1.8%	0.0%	0.0%		
Size, mm	25	25	25	0.743	
	(24-27)	(22-28)	(22-28)		
Outcome					
Primary implantation success	97.3%	100.0%	96.7%	1.000	
Minor residual flow	3.6%	0.0%	3.3%	1.000	
Procedure time, min (n=109)	65	60	86	0.088	
	(51-89)	(55-65)	(60-110)		
Procedure time without concomitant procedures, min (n=73)	64	65	85	0.366	
	(51-95)	(55-182)	(64-96)		
Dose area product, μGym^2 (n=117)	4220	8319	6929	0.149	
	(1058-8901)	(6052-10428)	(1218-12485)		
Fluoroscopy time, min (n=123)	15 (11-24)	14 (11-32)	17 (12-22)	0.795	
Amount of contrast, mL (n=148)	96 (64-146)	106 (70-145)	106 (66-154)	0.595	
Hospitalization duration, days (n=168)	3 (2-5)	2 (2-6)	3 (2-7)	0.225	
Procedural major complication	4.5%	13.3%	10.0%	0.159	
Cardiac tamponade	2.7%	6.7%	3.3%	0.512	
Access site complication	1.8%	6.7%	1.7%	0.376	
Ischemic stroke	0.0%	0.0%	3.3%	0.258	
Shock	0.9%	0.0%	1.7%	1.000	
Cardiac arrest	0.9%	0.0%	0.0%	1.000	
Procedural minor complication	9.9%	13.3%	16.7%	0.443	
Unplanned admission to intensive care unit	4.5%	6.7%	6.7%	0.679	

Bleeding requiring blood transfusion	0.9%	0.0%	8.3%	0.030	§
Acute kidney injury	0.9%	0.0%	3.3%	0.443	
Echocardiography at follow up					
Duration to TOE, days (n=111)	96±58	69±27	103±99	0.487	
Residual flow (n=110)	1.5%	0.0%	2.8%	1.000	
Major	0.0%	0.0%	0.0%		
Minor	1.5%	0.0%	2.8%		
Thrombus (n=108)	1.5%	0.0%	2.9%	1.000	

LAAC: left atrial appendage closure; PFO: patent foramen ovale; TOE: transoesophageal echocardiography. § no significant interaction between groups has been found in post-hoc testing.

Supplemental Table S3. Post-procedural anticoagulation strategy.

Parameter	Indication for LAAC			P value	
	Bleeding	Thrombo-embolism	Other	Overall	Post-hoc
Short-term antithrombotic therapy					
Duration, months (n=160)	3 (2-6)	3 (3-6)	3 (3-6)	0.309	
DAPT	47.7%	46.7%	63.3%	0.131	
Oral anticoagulation	17.1%	53.3%	16.7%	0.008	*,‡
DOAC alone	12.6%	20.0%	8.3%		
VKA alone	4.5%	0.0%	1.7%		
DOAC + SAPT	0.0%	20.0%	1.7%		
VKA + SAPT	0.0%	13.3%	5.0%		
SAPT	18.9%	0.0%	11.7%	0.114	
Aspirin	10.8%	0.0%	3.3%		
Clopidogrel	4.5%	0.0%	8.3%		
Aspirin + LMWH	2.7%	0.0%	0.0%		
Clopidogrel + LMWH	0.9%	0.0%	0.0%		
No antithrombotic therapy	16.2%	0.0%	8.3%	0.112	
Long-term antithrombotic therapy					
SAPT	42.3%	33.3%	48.3%	0.560	
Aspirin	36.0%	26.7%	45.0%		
Clopidogrel	6.3%	6.7%	3.3%		
No antithrombotic therapy	40.5%	33.3%	38.3%	0.869	
Oral anticoagulation	0.0%	26.7%	0.0%	<0.001	**,‡‡
DOAC	0.0%	20.0%	0.0%		
VKA	0.0%	6.7%	0.0%		
Other / not documented	17.1%	6.7%	13.3%	0.592	

DAPT: double antiplatelet therapy, DOAC: direct oral anticoagulant, LMWH: low molecular-weight heparin, SAPT: single antiplatelet therapy, VKA: vitamin K antagonist. The following symbols represent significant differences in post-hoc testing (after Bonferroni adjustment): bleeding vs embolism: * p<0.05, ** p<0.01; bleeding vs other: † p<0.05, †† p<0.01; embolism vs other: ‡ p<0.05, ‡‡ p<0.01; §no significant interaction in post-hoc testing found.